Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Figured it would be a fuck up...sold my last 1000 shares at 2.8 on wednesday
No short squeeze pop, just nonsense after/pre market trading. From technicals, can't break through resistance at the 3.5ish levels, so looks like more down for the near future.
Lol. I'm smoking marlboro....guessing you are on something stronger to still be positive about this POS company and its lying management
what $2 range is that?
They just gave up their only revenue stream apart from dilution. Sure, might not go bust, but more dilution will still kill the price.
Lost interest in this even though I still have some shares, so not posted in ages. This deal is a poor one IMHO. Last gasp attempt to scrape through not getting delisted from Nasdaq. Potential short squeeze at market opening will hopefully give a good opportunity to dump my remaining shares before the company goes bust.
ROW = rest of world
Premarket trading is looking brutal
1.65 based on the run up to 1.55 previously. But I want u to be correct ;)
1.65 target
Whale wisdom site also shows Vanguard reduced by 33k shares leaving 1,444,890 shares still held as of 31/12/15.
I read the page without being logged in, so saw SB's postings for a change. I haven't registered to view the full Vanguard 13F on Edgar, but from what I could find with the 31/12 reporting, Vanguard still have almost 1.5 mil shares of Apricus reported 31/12.
https://www.holdingschannel.com/funds/holding-apri/
I have no idea for when it will be, or for how much it will be, but it will happen, it is the only realistic way for Denner to offload his shares.
The usual suspect(s) are whining on a regular basis again here about how the company is doomed, so I thought I would post a reminder on how Denner tends to work. This piece is from fierce biotech website.
"Alex Denner
Hedge fund operator
Carl Icahn may have received most of the credit, and certainly the lion's share of the cash, created by his high-profile biotech raiding parties. But Alex Denner has been credited as the power behind the throne, a key player in the turnaround story of several top life sciences companies and a figure now promising to start stealing his own headlines now that he's jumped Icahn's ship to helm his own hedge fund.
The two came together at ImClone after both recognized the substantial amount of money that could be made by turning around the troubled company--after CEO Sam Waksal wound up in prison after the notorious insider trading scandal. Denner headed the executive committee that held the wheel, pushing a lead experimental drug--ramucirumab--from Phase I right into late-stage studies. And he helped engineer the $6.5 billion sale to Eli Lilly ($LLY) when everyone could focus on the value of Erbitux and its experimental cancer treatments.
Working directly under Icahn, it was Denner who played the good cop to Icahn's bad cop at Genzyme, where he made friends and influenced the raider's enemies. In the end he was the one that got the cheers when Sanofi stepped up with a $20 billion buyout. And while he may never make Jim Mullen's Christmas card list after playing the troublemaker on Biogen Idec's ($BIIB) board, who can ignore the buoyant honeymoon period that Biogen has enjoyed since the palace coup that led George Scangos into the top office?
Combining knowledge of the business with a clear connection to the science involved, Denner has created the template for the modern-day biotech turnaround story.
"Alex actually understands the science--and how to build that into a business," ex-con and ImClone founder Sam Waksal told Bloomberg. "When a company is broken, he knows what should be done to fix it."
As an inside player, few can compare to Denner. The big question now is where he plans to play next. And who will follow his game book on their own deals?"
Why would he sell before he can exercise all his warrants in July?
We know who put the 500k shares on the ask to keep the price down now anyway!
SB is wrong, this doesnt affect previous warrants to Sarissa. Sarissa still has about $1.35 average and will want profit, so all is not lost at least. I think they still target $2 a share minimum
The fight between Iran and Saudi will be done by Saudi keeping the taps on full. Oil will see $25 by end of January.
So, where is the update on RTD test results in the end of year synopsis??
"Apricus' second-generation room temperature Vitaros is currently under development."
Carlo, unless they answer the financing there may not be much pop at all even with good results. As for Denner offering to buy more at $1.83, I honestly cannot see any reason for him to do that when he can offer 90c
Germany is still not ordering any new product according to the 10Q
One more thing to factor into potential pps is the current climate of biotech stocks. Across the board small biotech stocks are getting hammered as investors are reluctant to take risks.
Denner is a long term investor based on past history. He might well be happy to push the price down to <$1 so he can pick up more shares at bargain prices.
Anyway, I have too many shares to dump them so I'm sticking with this ball and chain a while longer. ;)
Yes, back then hopes were high for Vitaros sales, the reality is that sales have been disappointing (IMO). 188k in royalties last quarter is pathetic. The good thing is with RTD approval there will be a few mill in milestone payments. Note I said approval not just positive test results.
The bigger issue is financing. They can either borrow more, dilute or have a deal for femprox rights. I think femprox unlikely and if they were going to dilute it should have been done on the US rights news when we were at 1.8x (although Denner could have blocked that option for his own reasons). That leaves borrowing more money.
Rprx have about 21 million shares outstanding with 60% tute ownership. They also have full worldwide rights with no obligation to make milestone or % royalties payments, so you can't compare the two companies like that.
The .5 is likely accurate if the trials are a bust, the 5 if successful, you are dreaming. Based on recent price action, if we go over 2 we will be doing well.
I think I might just take some more below the $1 mark next week. Based on last year we may even go down as low as 90c which is an absolute bargain IMHO.
More like $20-30
Nothing to do with connections at all. You just click a link on Deloitte's website to apply to be in the mix for selection and they grade you based on revenue increase over previous 3 years. Dead easy!
?Deloitte's Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth over a three year period. The ranking is compiled from applications submitted directly to the Technology Fast 500 Web site and public company database research conducted by Deloitte LLP.
Sarissa also showing no sign of being unhappy with the management decisions or progress. At least I haven't seen anything about him exercising the right to get a member on the board.
I suspect (and it is only my conjecture) that he has already cut a deal to take a 2nd allocation of shares based on successful Fispemifene trial results. This is why they have not made any visible attempts to sort out the funding for P3 yet.
Someone please delete this crap. This board is for discussion of Apricus, not politics/terrorism/religion!
Only shows increase of 169k when I checked just now.
Sarissa is a 'hedge' fund!
Same happened to APRI earlier in the year when they diluted at $1.8 to Sarissa, the PPS jumped up to about $2.75...oh how I wish I had taken my profits back then instead of being greedy.
There have been regular Corporate presentations in 2015, but after Sprout were initially rejected, Femprox went on the back burner and was only included as a very small byline in the presentations (or as SB stated numerous times FEMPROX IS DEAD!!!). If SB had wanted to, 2 minutes with Google and the keywords 'Femprox' and 'patent' would have brought that link, but he prefers not to worry overly much about the accuracy of his posts, provided they are dramatic.
http://www.sec.gov/Archives/edgar/data/1017491/000101749114000045/apricorporatepresentatio.htm
Bottom of page 18 - patent life to 2026 and applications filed for extension to 2032. Now please do your own DD next time instead of spreading false rumours!
Realistically, nothing will have much of a positive effect on the share price until the question of financing is answered.
So, sell your shares and take a hike somewhere else then if you are so convinced there is going to be bad news.
If you are not convinced enough there will be bad news then shut the **** up and quit posting unsubstantiated nonsense! In case you didn't notice, nobody here wants to see your nonsense. For some reason I still see your posts even though I set it to hide them ages ago.
Never heard before that being a loudmouth boorish dick was a medical condition....learn something new every day :)
Oh, ok...i was expecting more, but i am no expert for sure! I like your interpretation much more than mine Sci101
Oh, ok...i was expecting more, but i am no expert for sure! I like your interpretation much more than mine Sci101